The use of regional coordinating centers in large clinical trials: the DIG trial

被引:9
|
作者
Collins, JE
Martin, S
Kent, E
Liuni, C
Garg, R
Egan, D
机构
[1] Cooperat Studies Program Coordinating Ctr, VA Maryland Hlth Care Syst, Dept Vet Affairs, Perry Point, MD 21902 USA
[2] Univ Maryland, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA
[3] Univ Alberta, Edmonton, AB, Canada
[4] St Josephs Hosp, Hamilton, ON, Canada
[5] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada
[6] Eli Lilly & Co, Indianapolis, IN 46285 USA
[7] NHLBI, Div Epidemiol & Clin Applicat, Bethesda, MD 20892 USA
来源
CONTROLLED CLINICAL TRIALS | 2003年 / 24卷 / 06期
关键词
randomized clinical trials; large simple trial; heart failure; digoxin; regional coordinating centers;
D O I
10.1016/S0197-2456(03)00101-6
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The Digitalis Investigation Group (DIG) trial was a large simple clinical trial that involved 302 participating centers in the United States and Canada. In order to encourage participation by Canadian investigators, to provide additional help to what were expected to be largely research-inexperienced investigators in Canada, and to provide the study's data coordinating center with resources in Canada to deal with potentially different rules, regulations, and cultural differences, regional coordinating centers were established in four regions of Canada: the maritime provinces, Quebec, Ontario, and western Canada. Canadian centers recruited significantly better than their U.S. counterparts and had slightly better retention and follow-up. While it is not possible to declare that the regional coordinating centers were responsible for this improvement, it is believed that these regional centers did play a role. This role included being able to identify investigators who could be expected to do well, providing one-on-one training and instruction to investigators, and being able to solve problems and implement change in the relatively fewer centers in their regions. The regional coordinating center also reduced the intensity of the workload on the data coordinating center by serving as the primary point of contact for Canadian investigators. The use of regional coordinating centers in studies with a large number of participating centers is highly recommended. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:298S / 305S
页数:8
相关论文
共 50 条
  • [21] Beyond clinical trials-- The cost saving associated with dapagliflozin use in Portugal hospital clinical practice
    Brito, Dulce
    Fonsecac, Candida
    Francoe, Fatima
    Lopese, Vanessa
    Goncalves, Sara
    Baptistag, Rui
    Sequeirak, Joana
    Marquesl, Irene
    Regol, Rita
    Pimentap, Joana
    Silva-Cardosoq, Jose
    Lopesu, Margarida
    Almeidau, Mario
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2024, 43 (12) : 685 - 694
  • [22] Assessing consistent treatment effect in a multi-regional clinical trial: a systematic review
    Chen, Joshua
    Quan, Hui
    Binkowitz, Bruce
    Ouyang, S. Peter
    Tanaka, Yoko
    Li, Gang
    Menjoge, Shailendra
    Ibia, Ekopimo
    PHARMACEUTICAL STATISTICS, 2010, 9 (03) : 242 - 253
  • [23] Making Sense of Statistics in Clinical Trial Reports Part 1 of a 4-Part Series on Statistics for Clinical Trials
    Pocock, Stuart J.
    McMurray, John J. V.
    Collier, Tim J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 66 (22) : 2536 - 2549
  • [24] Integrating Quality of Life and Survival Outcomes Cardiovascular Clinical Trials Results From the PARTNER Trial
    Spertus, Jacob V.
    Hatfield, Laura A.
    Cohen, David J.
    Arnold, Suzanne V.
    Ho, Martin
    Jones, Philip G.
    Leon, Martin
    Zuckerman, Bram
    Spertus, John A.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2019, 12 (06):
  • [25] NEW DEVELOPMENTS IN THE CONDUCT AND MANAGEMENT OF MULTICENTER TRIALS - AN INTERNATIONAL REVIEW OF CLINICAL-TRIAL UNITS
    GLUUD, C
    SORENSEN, TIA
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1995, 9 (03) : 284 - 289
  • [26] Example-based illustrations of design, conduct, analysis and result interpretation of multi-regional clinical trials
    Quan, Hui
    Mao, Xuezhou
    Tanaka, Yoko
    Binkowitz, Bruce
    Li, Gang
    Chen, Josh
    Zhang, Ji
    Zhao, Peng-Liang
    Ouyang, Soo Peter
    Chang, Mark
    CONTEMPORARY CLINICAL TRIALS, 2017, 58 : 13 - 22
  • [27] Can We Do a Prospective Trial for Fetal Tachycardia? The Barriers to Clinical Trials in Small Patient Populations
    Saul, J. Philip
    Cain, Nicole B.
    CIRCULATION, 2011, 124 (16) : 1703 - 1705
  • [28] Pragmatic Design of Randomized Clinical Trials for Heart Failure Rationale and Design of the TRANSFORM-HF Trial
    Greene, Stephen J.
    Velazquez, Eric J.
    Anstrom, Kevin J.
    Eisenstein, Eric L.
    Sapp, Shelly
    Morgan, Shelby
    Harding, Tina
    Sachdev, Vandana
    Ketema, Fassil
    Kim, Dong-Yun
    Desvigne-Nickens, Patrice
    Pitt, Bertram
    Mentz, Robert J.
    JACC-HEART FAILURE, 2021, 9 (05) : 325 - 335
  • [29] Characteristics and Outcomes of Clinical Trials on Gene Therapy in Noncongenital Cardiovascular Diseases: Cross-sectional Study of Three Clinical Trial Registries
    Pinczak, Witold
    Trzcinska, Sylwia
    Kaminski, Mikolaj
    JMIR FORMATIVE RESEARCH, 2022, 6 (04)
  • [30] Memantine and Acetylcholinesterase Inhibitor Use in Alzheimer's Disease Clinical Trials: Potential for Confounding by Indication
    Huisa, Branko N.
    Thomas, Ronald G.
    Jin, Shelia
    Oltersdorf, Tilman
    Taylor, Curtis
    Feldman, Howard H.
    JOURNAL OF ALZHEIMERS DISEASE, 2019, 67 (02) : 707 - 713